Akers Biosciences (AKER) – Company Press Releases
-
Contango Announces the Appointment of Two New Directors
-
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
-
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial
-
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board
-
Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals
-
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
-
Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission
-
Akers Biosciences Responds to Erroneous Earnings Call Press Release
-
AKERS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKER and Encourages Investors to Contact the Firm
-
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent
-
REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals
-
Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement
-
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
-
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
-
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies
-
Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies
-
Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
-
Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
-
Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
-
Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
-
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
-
Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
-
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
-
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
-
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
-
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
-
Aker BP ASA: Fourth Quarter 2019 Results and Capital Markets Update
-
Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation
-
Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation
-
Akers BioSciences Regains Compliance with Nasdaq Listing Standards
-
Akers BioSciences Regains Compliance with Nasdaq Listing Standards
-
Akers Biosciences to Present at the Investor Summit on December 17th in Philadelphia
-
Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering
-
Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering
-
Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada
-
Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada
-
Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering
-
Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering
-
Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry
-
Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry
-
Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split
-
Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split
Back to AKER Stock Lookup
